• Real Time Chart Real Time Chart
  • Stock Profile Stock Profile
  • Balance Sheet

  • Symbol Info Symbol Info
  • Symbol Over View Symbol Over View
  • Technical Analysis Technical Analysis

IBRX stock profile

ImmunityBio Inc Company Profile

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.

Company information

  • Company Name ImmunityBio Inc
  • Industry Biological Product (except Diagnostic) Manufacturing
  • CEO Patrick Soon-Shiong
  • Security Name ImmunityBio Inc
  • Sector Manufacturing
  • Employees 725
  • Exchange NASDAQ
  • Country US
  • State California
  • City San Diego
  • Address 3530 John Hopkins Ct
  • Phone 18586330300
  • Website https://immunitybio.com
  • Zip 92121-1121

Peers

  • OVAT-CA
  • OVID
  • OVIT
  • OYST

Top Executives

  • Entity Name
  • Position
  • Report Date
  • Adcock Richard
    350000
    2022-03-25
  • SOON-SHIONG PATRICK
    350000
    2022-03-25
  • BLASZYK MICHAEL D
    167937
    2022-06-15
  • Brennan John Owen
    167937
    2022-06-15
  • Clark Wesley
    167937
    2022-06-15
  • Cohen Cheryl
    167937
    2022-06-15
  • MAXWELL LINDA
    167937
    2022-06-15
  • Selecky Christobel
    167937
    2022-06-15
  • Sachs David C.
    125000
    2022-03-25
  • Simon Barry J.
    10714
    2022-03-25